Notice Type
Departmental
Consent to the Distribution of Changed Medicines Pursuant to section 20 of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of the changed medicines which were referred to the Minister of Health under the provisions of section 24 (5) of the Act, and are set out in the Schedule hereto: Schedule Name and Strength Form Name and Address of Manufacturer Proprietary Name(if any) Tablet 1 28 Conjugated estrogens 0.625 mg; Tablet 2 28 medroxyprogesterone acetate 5 mg Tablets Wyeth Medical Ireland, Newbridge, County Kildare, Eire and Wyeth Australia Pty Limited, Smithfield, New South Wales, Australia Menoprem 2.5 Continuous Tablet 1 28 Conjugated estrogens 0.625 mg; Tablet 2 14 medroxyprogesterone acetate 5 mg Tablets Wyeth Medical Ireland, Newbridge, County Kildare, Eire and Wyeth Australia Pty Limited, Smithfield, New South Wales, Australia Menoprem 5 Urofollitropin 75 IU, 150 IU in 3 mL and diluent (sodium chloride 0.9 % w/v in 1 mL) Injection, powder, ampoule; Diluent, ampoule Industria Farmaceutica Serono SpA., Rome, Italy; Laboratoires Serono SA., Aubonne, Switzerland and Serono Pharm SpA., Bari, Italy Metrodin HP Conjugated estrogens 0.625 mg, medroxyprogesterone acetate 2.5 mg Tablet Wyeth Medical Ireland, Newbridge, County Kildare, Eire and Wyeth Australia Pty Limited, Smithfield, New South Wales, Australia Premia 2.5 Continuous Tablet 1 14 Conjugated estrogens 0.625 mg; Tablet 2 14 medroxyprogesterone acetate 5 mg Tablets Wyeth Medical Ireland, Newbridge, County Kildare, Eire and Wyeth Australia Pty Limited, Smithfield, New South Wales, Australia Premia 5 Conjugated estrogens 0.625 mg, medroxyprogesterone acetate 5 mg Tablet Wyeth Medical Ireland, Newbridge, County Kildare, Eire and Wyeth Australia Pty Limited, Smithfield, New South Wales, Australia Premia 5 Continuous Didanosine 25 mg, 50 mg, 100 mg, 150 mg Tablets, chewable/ dispersible Bristol-Myers Squibb Co, Evansville, Indianna, United States of America Videx Dated this 12th day of August 1997. G. R. BOYD, Chief Advisor, Regulation and Safety, pursuant to delegation given by the Minister of Health on the 20th day of February 1997.
Publication Date
21 Aug 1997

Notice Number

1997-go5688

Page Number

2329